NewAmsterdam Pharma Company N.V. — Company profile
Healthcare · Biotechnology · Netherlands
Last price 20.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Details
| Name | NewAmsterdam Pharma Company N.V. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 100 |
| Founded | 2019 |
| Ceo | Michael Davidson |
| Country | Netherlands |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | NL00150012L7 |
| Cik | 1936258 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President and Executive Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board and Director |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Robert W. Gunning CPA, CGMA | Principal Accounting Officer, Vice President and Controller |
| Matthew Philippe | Executive Vice President and Head of Investor Relations |
| Michael F. Marino Esq. | Chief Legal Officer and Corporate Secretary |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations |
| Maryellen McQuade | Chief People Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Strategy and Business Officer |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
Contact
| Address | Gooimeer 2-35, Naarden, 1411 DC, Netherlands |
| Phone | 31 35 206 2971 |
| Website | https://www.newamsterdampharma.com |